前病毒潜伏、持续性HIV感染及潜伏逆转剂的研发
本文综述了HIV-1潜伏前病毒在有效抗逆转录病毒治疗(ART)下持续存在、停药后导致病毒反弹的机制,指出诱导潜伏前病毒是潜伏逆转剂(LRA)的治疗目标。文章讨论了LRA研发面临的生物学复杂性、宿主靶点毒性及检测方法验证不足等障碍,并提到新型LRA正进入与病毒清除策略的联合测试。
要点
- 潜伏前病毒是HIV治愈的核心障碍,停药后反弹。
- LRA通过诱导潜伏前病毒表达实现潜伏逆转。
- LRA研发面临宿主靶点毒性和检测方法未充分验证的挑战。
核心结论
- 诱导潜伏前病毒是HIV治愈策略的关键,LRA研发虽面临多重不确定性但已有进展并进入联合测试阶段。
研究设计与样本
- 本文为综述,未报告系统检索范围或样本量。
主要发现
- 有效ART下持续存在的静息前病毒基因组可在治疗中断后引发反弹病毒血症。
- HIV潜伏生物学复杂且尚未完全阐明。
- LRA的潜在靶点为宿主因子,宿主导向治疗在临床稳定个体中可能具有不可接受的毒性。
- 测量潜伏逆转和评估候选疗效的检测方法复杂且未充分验证。
- 新型LRA正在研发中并开始与病毒清除策略进行联合测试。
临床怎么用
- 关注LRA与免疫治疗联合清除持续感染细胞的研究进展,以期实现可测量的HIV治愈进展。
局限性
- HIV潜伏生物学复杂且不完全清楚。
- 宿主导向LRA的潜在毒性在临床稳定个体中可能不可接受。
- 潜伏逆转检测方法复杂且未充分验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Quiescent proviral genomes that persist during human immunodeficiency virus type 1 (HIV-1) infection despite effective antiretroviral therapy (ART) can fuel rebound viremia after ART interruption and is a central obstacle to the cure of HIV infection. The induction of quiescent provirus is the goal of a new class of potential therapeutics, latency reversing agents (LRAs). The discovery, development, and testing of HIV LRAs is a key part of current efforts to develop latency reversal and viral clearance strategies to eradicate established HIV infection. The development of LRAs is burdened by many uncertainties that make drug discovery difficult. The biology of HIV latency is complex and incompletely understood. Potential targets for LRAs are host factors, and the potential toxicities of host-directed therapies in individuals that are otherwise clinically stable may be unacceptable. Assays to measure latency reversal and assess the effectiveness of potential therapeutics are complex and incompletely validated. Despite these obstacles, novel LRAs are under development and beginning to enter combination testing with viral clearance strategies. It is hoped that the steady advances in the development of LRAs now being paired with emerging immunotherapeutics to clear persistently infected cells will soon allow measurable clinical advances toward an HIV cure.
引用
- Margolis DM, Archin NM. Proviral Latency, Persistent Human Immunodeficiency Virus Infection, and the Development of Latency Reversing Agents. J Infect Dis. 2017. PMID: 28520964. doi:10.1093/infdis/jiw618
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。